Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC. | v380209_ex31-1.htm |
| EX-32.1 - EXHIBIT 32.1 - OPIANT PHARMACEUTICALS, INC. | v380209_ex32-1.htm |
| EXCEL - IDEA: XBRL DOCUMENT - OPIANT PHARMACEUTICALS, INC. | Financial_Report.xls |
| 10-Q - FORM 10-Q - OPIANT PHARMACEUTICALS, INC. | v380209_10q.htm |
| EX-31.2 - EXHIBIT 31.2 - OPIANT PHARMACEUTICALS, INC. | v380209_ex31-2.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Lightlake Therapeutics Inc. (the “Company") for the period ended April 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Kevin Pollack as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: June 10, 2014
| By: | /s/ Kevin Pollack | ||
| Kevin Pollack | |||
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|||